(Q34591128)

3 August 2017

1 reference

title

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. (English)

1 reference

3 August 2017

1 reference

Kristen M Hege

1

1 reference

3 August 2017

Karin Jooss

series ordinal

2

1 reference

3 August 2017

Drew Pardoll

series ordinal

3

1 reference

3 August 2017

language of work or name

1 reference

1 September 2006

1 reference

International Reviews of Immunology

3 August 2017

1 reference

3 August 2017

25

1 reference

3 August 2017

5-6

1 reference

3 August 2017

321-352

1 reference

Human tumor antigens recognized by T cells

3 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Immunological foundations to the quest for new vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

GM-CSF-based cellular vaccines: a review of the clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

GM-CSF-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

A GM-CSF/CD40L producing cell augments anti-tumor T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

VEGF as a mediator of tumor-associated immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony-stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Theratope vaccine (STn-KLH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180600992498

10.1080/08830180600992498

21 January 2018

Identifiers

DOI

1 reference

release_s5z2f2wn4zfrhbpwqd5mk5nmsi

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/s5z2f2wn4zfrhbpwqd5mk5nmsi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference